Business
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company u
About this update from Tenax Therapeutics, Inc.
[{"type":"image","alt":"Tenax Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenax Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/db9e802274359b8735193ba3952d6da1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8zXg8OV.BHgaYSnVk00_yg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/db9e802274359b8735193ba3952d6da1","width":300,"height":114}},"lazy":false},{"type":"text","content":"Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study","length":97,"tagName":"p"},{"type":"text","content":"LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026","length":105,"tagName":"p"},{"type":"text","content":"Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027","length":97,"tagName":"p"},{"type":"text","content":"CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD), the primary endpoint. Based on these results, Tenax confirmed the target enrollment remains unchanged, and reiterated that enrollment is expected to complete in the first half of 2026.","length":650,"tagName":"p"},{"type":"text","content":"LEVEL is an ongoing, registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) in the United States and Canada. The prespecified, blinded review of the standard deviation in 6MWD change observed in the first 150 randomized, placebo-controlled patients, yielded a result of less than the assumed 55 meters.","length":425,"tagName":"p"},{"type":"text","content":"“We are very pleased with the outcome of the BSSR, a derisking element built into the LEVEL protocol from the start. Key powering assumptions we based on data from the Phase 2 HE...